^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JSI-1187

    i
    Other names: JSI-1187, JSI-1187-01
    Company:
    JS InnoPharm
    Drug class:
    ERK2 inhibitor, ERK1 inhibitor
    Related drugs:
    9ms
    JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
    P1, N=71, Suspended, JS InnoPharm, LLC | N=124 --> 71 | Trial primary completion date: Dec 2023 --> Jun 2024
    Enrollment change • Trial primary completion date • Combination therapy • Metastases
    |
    MAP2K1 (Mitogen-activated protein kinase kinase 1) • NF1 (Neurofibromin 1) • RASA1 (RAS P21 Protein Activator 1)
    |
    BRAF V600E • BRAF V600K
    |
    Tafinlar (dabrafenib) • JSI-1187
    10ms
    ERK Inhibitor JSI-1187 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, JS InnoPharm, LLC
    New P1 trial
    |
    JSI-1187
    1year
    JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
    P1, N=124, Suspended, JS InnoPharm, LLC | Recruiting --> Suspended | Trial primary completion date: May 2023 --> Dec 2023
    Trial suspension • Trial primary completion date • Combination therapy • Metastases
    |
    MAP2K1 (Mitogen-activated protein kinase kinase 1) • NF1 (Neurofibromin 1) • RASA1 (RAS P21 Protein Activator 1)
    |
    BRAF V600E • BRAF V600K
    |
    Tafinlar (dabrafenib) • JSI-1187
    over1year
    Efficacy of JSI-1187 or VIC-1911 in combination with KRAS G12C inhibitors for the treatment of KRAS G12C-mutated non-small cell lung cancer and colorectal cancer (AACR 2023)
    JSI-1187 or VIC-1911 combined with sotorasib or adagrasib demonstrated marked enhancement of the antitumor effect compared with single-agent treatment in a H2122 mouse xenograft model. Additionally, the antitumor growth effect of JSI-1187 and sotorasib was significantly better than the combination of the MEK inhibitor, trametinib, and sotorasib...In addition, the combination of JSI-1187 and sotorasib demonstrated a significant increase in tumor growth inhibition in a CRC PDX model. Taken together, our preclinical studies suggest that the combination of an ERK inhibitor, JSI-1187, or an AURKA inhibitor, VIC-1911, may potentially overcome the primary resistance and prevent or delay the acquired resistance to G12C inhibitors.
    Clinical • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • RAS mutation • KRAS G12
    |
    Mekinist (trametinib) • Lumakras (sotorasib) • Krazati (adagrasib) • VIC-1911 • JSI-1187
    almost2years
    JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
    P1, N=124, Recruiting, JS InnoPharm, LLC | Trial completion date: Nov 2023 --> Nov 2024
    Trial completion date • Combination therapy • Metastases
    |
    MAP2K1 (Mitogen-activated protein kinase kinase 1) • NF1 (Neurofibromin 1) • RASA1 (RAS P21 Protein Activator 1)
    |
    BRAF V600E • BRAF V600K
    |
    Tafinlar (dabrafenib) • JSI-1187
    over4years
    JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
    P1, N=121, Recruiting, JS InnoPharm, LLC
    New P1 trial • Combination therapy
    |
    MAP2K1 (Mitogen-activated protein kinase kinase 1) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • BRAF V600
    |
    Tafinlar (dabrafenib) • JSI-1187